Company Name: |
JW & Y Pharmlab Co., Ltd.
|
Tel: |
021-64340559 13651849907; |
Email: |
xinyu_shi@jwypharmlab.com.cn |
Products Intro: |
Product Name:N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride CAS:1373232-26-8 Purity:94% Package:mg;g;kg等可分装
|
|
| N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride Basic information |
Product Name: | N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride | Synonyms: | N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride;Cl-Amidine (hydrochloride);Cl-Amidine (hydrochloride) - Sold under license from the University of South Carolina under U.S. Patent No. 7,964,363;Cl amidine hydrochloride,miRNA-16,Protein Arginine Deiminase,Cl-amidine,inhibit,MicroRNA,Peptidylarginine Deiminase,Clamidine hydrochloride,Inhibitor,miRNA,microRNA-16,colitis,sepsis,Apoptosis,miR-16 | CAS: | 1373232-26-8 | MF: | C14H20Cl2N4O2 | MW: | 347.2402 | EINECS: | | Product Categories: | | Mol File: | 1373232-26-8.mol | ![N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride Structure](CAS/20180703/GIF/1373232-26-8.gif) |
| N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride Chemical Properties |
storage temp. | Store at -20°C | solubility | DMF: 14 mg/ml; DMSO: 50 mg/ml; Ethanol: 20 mg/ml; PBS (pH 7.2): 3 mg/ml | form | A crystalline solid | color | White to light yellow |
| N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride Usage And Synthesis |
Description | Cl-Amidine is an irreversible inhibitor of protein arginine deiminases (PADs; IC50s = 0.8, 6.2, and 5.9 μM for PAD1, PAD3, and PAD4, respectively). It is cytotoxic to HL-60, MCF-7, and HT-29 cancer cells (IC50s = 0.25, 0.05, and 1 μM, respectively). Cl-amidine (50 mg/kg) reduces ex vivo extracellular neutrophil extracellular trap (NET) formation and increases survival in a mouse model of sepsis induced by cecal ligation and puncture (CLP). It also decreases the citrulline content in serum and joints and reduces the development of IgG autoantibodies in a mouse model of collagen-induced arthritis in a dose-dependent manner. |
| N-[(1S)-1-(Aminocarbonyl)-4-[(2-chloro-1-iminoethyl)amino]butyl]-benzamide hydrochloride Preparation Products And Raw materials |
|